A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 252 participants.

Also called NCT01301066

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 252 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01301066
Other papers using this trial's data
  • Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV AIDS (London, England), 2017-03-27 DOI, PubMed 28252528, PMC5382495 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Greater remnant lipoprotein cholesterol reduction with pitavastatin compared with pravastatin in HIV-infected patients AIDS (London, England), 2017-04-24 DOI, PubMed 28121706
  • Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial The lancet. HIV, 2017-07 DOI, PubMed 28416195 PubMed links an erratum for this paper. Erratum: PMID 28457797

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01301066. Randomized; double masking; primary purpose treatment. Start 2010-12 (registry gives no type); primary completion 2013-03 (actual). Results posted on 2014-04-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects
Condition
Dyslipidemia
Intervention (Drug)
Pitavastatin
Intervention (Drug)
Pravastatin
Lead sponsor
Kowa Research Institute, Inc. (class: industry)
Collaborator
Kowa Pharmaceuticals America, Inc. (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01301066
Content hash
0fee5f386b00305b7c2daa3b3888ed7170d3e4ce52a1c25066e02e51caec95e7